Attovia Therapeutics (NASDAQ:ATTO) Director Buys $1,785,000.00 in Stock

Posted by Lindsey Winhoffer on Aug 14th, 2026

Attovia Therapeutics, Inc. (NASDAQ:ATTO – Get Free Report) Director Colin Walsh bought 85,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The stock was bought at an average cost of $21.00 per share, for a total transaction of $1,785,000.00. Following the completion of the transaction, the director directly owned 85,000 shares in the company, valued at approximately $1,785,000. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Colin Walsh also recently made the following trade(s):

On Wednesday, August 5th, Colin Walsh sold 105,807 shares of Attovia Therapeutics stock. The shares were sold at an average price of $21.28, for a total transaction of $2,251,572.96.
On Thursday, August 6th, Colin Walsh acquired 500,000 shares of Attovia Therapeutics stock. The stock was bought at an average price of $17.00 per share, with a total value of $8,500,000.00.

Attovia Therapeutics Stock Performance

Shares of ATTO stock opened at $19.18 on Friday. Attovia Therapeutics, Inc. has a 1 year low of $16.15 and a 1 year high of $22.79.

Institutional Investors Weigh In On Attovia Therapeutics

A hedge fund recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. lifted its holdings in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO – Free Report) by 23.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 164,358 shares of the company’s stock after acquiring an additional 31,189 shares during the period. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent reporting period.

Attovia Therapeutics Company Profile

(Get Free Report)

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.